|Bid||2.0700 x 1000|
|Ask||2.0800 x 800|
|Day's Range||2.0300 - 2.1200|
|52 Week Range||0.9300 - 3.5400|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.06|
New York, New York--(Newsfile Corp. - November 17, 2020) - Enthusiasm is surrounding Pfizer's and Moderna's announcement of COVID-19 vaccine candidates that may soon become ripe for approval. But, in all fairness to the progress, tempering some of the excitement is warranted. There are two significant concerns. First, both Pfizer and Moderna candidates use synthetic mRNA technology to activate the immune system against the virus and must be kept at minus 70 ...
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Topline Results for SGX942 in 4Q20 Soligenix, Inc. (NASDAQ:SNGX) is currently conducting the Phase 3 DOM-INNATE ( D usquetide treatment in O ral M ucositis – by modulating INNATE immunity) trial of SGX942 in the treatment of oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...